Stomach Cancer IIIB

What IIIB Means

Very large tumor (T4a or T4b) with multiple involved lymph nodes (N2-3), or any T with 7+ involved nodes. Peritoneal involvement may be present.

Treatment Approach for IIIB

Perioperative chemotherapy (neoadjuvant and adjuvant FOLFOX/CAPOX). For HER2-positive tumors, consider adding trastuzumab or ramucirumab. Palliative approaches if unresectable.

Survival Rates and Prognosis

The 5-year survival rate for stomach cancer at IIIB is approximately 5-year survival approximately 15–25%. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.

Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.

How Other Stages Compare

Stage	5-Year Survival	Treatment
Stage IA	5-year survival approximately 70–75%	Endoscopic resection for very small lesions, or partial gastrectomy with D2…
Stage IB	5-year survival approximately 60–65%	Subtotal or total gastrectomy with D2 lymph node dissection. Adjuvant…
Stage II	5-year survival approximately 40–50%	Gastrectomy with D2 dissection. Adjuvant chemotherapy with…
Stage IIIA	5-year survival approximately 25–35%	Neoadjuvant (preoperative) chemotherapy with FOLFOX or CAPOX for 3 cycles,…
Stage IV (Metastatic)	5-year survival approximately 5–10% (median overall survival 8–14 months with modern therapy)	Palliative chemotherapy with fluoropyrimidine-based regimens (FOLFOX, CAPOX)….